DK2437742T3 - Nye sammensætninger til behandling af cmt og beslægtede sygdomme - Google Patents

Nye sammensætninger til behandling af cmt og beslægtede sygdomme

Info

Publication number
DK2437742T3
DK2437742T3 DK10724399.0T DK10724399T DK2437742T3 DK 2437742 T3 DK2437742 T3 DK 2437742T3 DK 10724399 T DK10724399 T DK 10724399T DK 2437742 T3 DK2437742 T3 DK 2437742T3
Authority
DK
Denmark
Prior art keywords
related diseases
new compositions
treating cmt
cmt
treating
Prior art date
Application number
DK10724399.0T
Other languages
English (en)
Inventor
Daniel Cohen
Serguei Nabirochkin
Ilya Chumakov
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Application granted granted Critical
Publication of DK2437742T3 publication Critical patent/DK2437742T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK10724399.0T 2009-06-02 2010-05-28 Nye sammensætninger til behandling af cmt og beslægtede sygdomme DK2437742T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305506A EP2263665A1 (en) 2009-06-02 2009-06-02 New compositions for treating CMT and related disorders
PCT/EP2010/057438 WO2010139627A1 (en) 2009-06-02 2010-05-28 New compositions for treating cmt and related disorders

Publications (1)

Publication Number Publication Date
DK2437742T3 true DK2437742T3 (da) 2014-11-03

Family

ID=41168603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10724399.0T DK2437742T3 (da) 2009-06-02 2010-05-28 Nye sammensætninger til behandling af cmt og beslægtede sygdomme

Country Status (25)

Country Link
US (4) US20120088744A1 (da)
EP (4) EP2263665A1 (da)
JP (1) JP5875191B2 (da)
KR (1) KR101740336B1 (da)
CN (2) CN104688737B (da)
AR (1) AR077540A1 (da)
AU (1) AU2010255802B2 (da)
BR (1) BRPI1013302B1 (da)
CA (1) CA2763495C (da)
CY (1) CY1115736T1 (da)
DK (1) DK2437742T3 (da)
EA (1) EA024523B1 (da)
ES (2) ES2641191T3 (da)
HR (1) HRP20141009T1 (da)
IL (1) IL216621A (da)
MX (1) MX345287B (da)
NZ (1) NZ596656A (da)
PL (1) PL2437742T3 (da)
PT (1) PT2437742E (da)
SG (1) SG176275A1 (da)
SI (1) SI2437742T1 (da)
SM (1) SMT201400160B (da)
UA (1) UA110013C2 (da)
WO (1) WO2010139627A1 (da)
ZA (1) ZA201109423B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US9867837B2 (en) * 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
SI2560631T1 (sl) 2011-03-01 2014-06-30 Pharnext Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
FR2987271B1 (fr) * 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
WO2014163380A1 (ko) * 2013-04-02 2014-10-09 사회복지법인 삼성생명공익재단 샤르코-마리-투스 질환 치료제의 스크리닝 방법 및 이에 이용되는 자가분화운동신경세포
SMT201800534T1 (it) * 2013-06-05 2019-01-11 Pharnext Soluzioni orali stabili per principi attivi farmaceutici combinati
EP3079688B1 (en) * 2013-12-13 2017-11-22 Pierre Fabre Médicament A chromone derivative as a dopamine d3 receptor antagonist for its use in the treatment of autism spectrum disorder
WO2015121218A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
WO2015124763A1 (en) * 2014-02-24 2015-08-27 Pharnext New compositions for treating mechanical neuronal injuries
WO2016191241A1 (en) * 2015-05-27 2016-12-01 Mmc & Company Llc Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
CN111658643B (zh) * 2020-07-31 2021-12-07 西安交通大学医学院第一附属医院 雷帕霉素在难治性Graves病中的制药应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
CA2305179A1 (en) * 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Oral administration preparation
JP2002526417A (ja) 1998-10-02 2002-08-20 セルトリックス ファーマシューティカルズ，インコーポレイテッド 非甲状腺性疾患の治療方法
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) * 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
ATE510534T1 (de) 2002-03-14 2011-06-15 Euro Celtique Sa Naltrexonhydrochlorid-zusammensetzungen
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
CA2495917A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
AU2004229551A1 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
WO2005032555A2 (en) 2003-09-25 2005-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20050191343A1 (en) * 2003-11-26 2005-09-01 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
ATE511392T1 (de) 2007-01-11 2011-06-15 Xenoport Inc Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2065821A1 (en) 2007-11-30 2009-06-03 Pharnext Novel disease treatment by predicting drug association
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
SI2560631T1 (sl) 2011-03-01 2014-06-30 Pharnext Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
SMT201800534T1 (it) 2013-06-05 2019-01-11 Pharnext Soluzioni orali stabili per principi attivi farmaceutici combinati
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
US20120088744A1 (en) 2012-04-12
BRPI1013302B1 (pt) 2022-07-12
US9427436B1 (en) 2016-08-30
US10905686B2 (en) 2021-02-02
WO2010139627A1 (en) 2010-12-09
SG176275A1 (en) 2012-01-30
IL216621A0 (en) 2012-02-29
EA024523B1 (ru) 2016-09-30
ES2523268T3 (es) 2014-11-24
PL2437742T3 (pl) 2015-03-31
MX2011012817A (es) 2011-12-16
EP3246025A1 (en) 2017-11-22
KR101740336B1 (ko) 2017-06-08
PT2437742E (pt) 2014-11-04
US11672796B2 (en) 2023-06-13
CA2763495A1 (en) 2010-12-09
US20160263104A1 (en) 2016-09-15
JP2012528818A (ja) 2012-11-15
JP5875191B2 (ja) 2016-03-02
IL216621A (en) 2016-05-31
CY1115736T1 (el) 2017-01-25
KR20120027353A (ko) 2012-03-21
NZ596656A (en) 2013-08-30
CN102458387A (zh) 2012-05-16
CA2763495C (en) 2018-06-26
US20210322402A1 (en) 2021-10-21
BRPI1013302A2 (en) 2018-01-09
AU2010255802A1 (en) 2011-12-22
US20180250290A1 (en) 2018-09-06
SI2437742T1 (sl) 2015-02-27
AU2010255802B2 (en) 2014-08-14
MX345287B (es) 2017-01-24
EP2437742B1 (en) 2014-08-06
AR077540A1 (es) 2011-09-07
ES2641191T3 (es) 2017-11-08
HK1170150A1 (en) 2013-02-22
CN102458387B (zh) 2015-01-28
EP2823817B1 (en) 2017-06-21
HRP20141009T1 (hr) 2015-01-30
CN104688737A (zh) 2015-06-10
ZA201109423B (en) 2012-09-26
EP2823817A1 (en) 2015-01-14
EP2437742A1 (en) 2012-04-11
EP2263665A1 (en) 2010-12-22
HK1206590A1 (en) 2016-01-15
CN104688737B (zh) 2019-11-08
UA110013C2 (uk) 2015-11-10
EA201101686A1 (ru) 2012-06-29
SMT201400160B (it) 2015-01-15

Similar Documents

Publication Publication Date Title
DK2361090T3 (da) Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK2346864T3 (da) Nye forbindelser anvendelige for behandling af degenerative og inflammatoriske sygdomme
DK2419732T3 (da) Prionfrie nanopartikelsammensætninger og fremgangsmåder
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK3128014T3 (da) Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger
DK2419670T3 (da) Leveringsmetode og sammensætninger
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK2894165T5 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2473034T3 (da) Frøbehandlingssammensætninger og fremgangsmåde
BRPI1011587A2 (pt) compostos e composições terapèuticas
DK2890780T3 (da) Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
FR2941462B1 (fr) Composition decapante
DK2442791T3 (da) Former til dosering af apixaban
DK2726511T3 (da) Sammensætninger, anvendelser og fremgangsmåder til behandling af stofskiftesygdomme og -lidelser
DK2766483T3 (da) Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK3460056T3 (da) Terapeutiske nukleasesammensætninger og fremgangsmåder
DK2382009T3 (da) Bestrålingsindretning
DK2688557T3 (da) Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK2398902T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
DK2446246T3 (da) Indretning og fremgangsmåde til udvælgelse af partikler
BRPI1008326A2 (pt) Composições e métodos para controlar nanatódeos
DK2830654T3 (da) Metoder og sammensætninger til behandling af inflammation